Washington Capital Management Inc. acquired a new position in Humana Inc. (NYSE:HUM - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 1,700 shares of the insurance provider's stock, valued at approximately $431,000.
Several other institutional investors have also recently added to or reduced their stakes in HUM. Creative Financial Designs Inc. ADV grew its holdings in Humana by 244.0% during the 3rd quarter. Creative Financial Designs Inc. ADV now owns 86 shares of the insurance provider's stock worth $27,000 after acquiring an additional 61 shares in the last quarter. Atwood & Palmer Inc. purchased a new stake in Humana in the 3rd quarter valued at approximately $29,000. Ashton Thomas Securities LLC acquired a new position in Humana during the third quarter worth $31,000. Your Advocates Ltd. LLP boosted its position in shares of Humana by 81.8% during the 3rd quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider's stock worth $32,000 after purchasing an additional 45 shares in the last quarter. Finally, LRI Investments LLC lifted its position in shares of Humana by 1,021.4% during the 3rd quarter. LRI Investments LLC now owns 157 shares of the insurance provider's stock valued at $50,000 after acquiring an additional 143 shares during the period. Institutional investors and hedge funds own 92.38% of the company's stock.
Insider Activity
In related news, insider Timothy S. Huval sold 3,703 shares of the firm's stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total value of $948,930.78. Following the completion of the transaction, the insider now directly owns 8,181 shares of the company's stock, valued at approximately $2,096,463.06. This trade represents a 31.16 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.32% of the stock is owned by corporate insiders.
Humana Price Performance
Shares of Humana stock traded up $1.68 during mid-day trading on Thursday, reaching $295.91. 624,827 shares of the stock were exchanged, compared to its average volume of 1,502,602. The company has a market cap of $35.63 billion, a price-to-earnings ratio of 26.21, a price-to-earnings-growth ratio of 2.15 and a beta of 0.55. Humana Inc. has a fifty-two week low of $213.31 and a fifty-two week high of $406.46. The firm has a 50-day simple moving average of $275.44 and a 200 day simple moving average of $303.07. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.67.
Humana (NYSE:HUM - Get Free Report) last issued its quarterly earnings data on Wednesday, October 30th. The insurance provider reported $4.16 EPS for the quarter, topping the consensus estimate of $3.48 by $0.68. The business had revenue of $29.30 billion for the quarter, compared to the consensus estimate of $28.66 billion. Humana had a return on equity of 13.20% and a net margin of 1.18%. On average, sell-side analysts predict that Humana Inc. will post 16.11 EPS for the current fiscal year.
Wall Street Analyst Weigh In
HUM has been the subject of a number of research reports. Sanford C. Bernstein upgraded shares of Humana from a "market perform" rating to an "outperform" rating and set a $308.00 target price for the company in a research report on Tuesday, October 8th. UBS Group cut their target price on shares of Humana from $380.00 to $250.00 and set a "neutral" rating for the company in a research note on Friday, October 4th. Truist Financial boosted their price objective on shares of Humana from $260.00 to $290.00 and gave the company a "hold" rating in a research report on Monday, January 6th. Barclays lifted their target price on shares of Humana from $253.00 to $255.00 and gave the stock an "equal weight" rating in a research note on Wednesday, January 22nd. Finally, Oppenheimer reduced their price target on Humana from $400.00 to $280.00 and set an "outperform" rating on the stock in a research note on Thursday, October 3rd. Nineteen equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, Humana has an average rating of "Hold" and a consensus price target of $297.68.
View Our Latest Stock Analysis on HUM
About Humana
(
Free Report)
Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
Featured Stories
Before you consider Humana, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Humana wasn't on the list.
While Humana currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
